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Background: Malaria rapid diagnostic tests (RDTs) are commonly used in Médecins Sans Frontières (MSF)
programmes to detect acute malaria infection. Programmes in regions with both Plasmodium falciparum and
non-falciparum malaria (i.e. Plasmodium ovale, Plasmodium malariae and Plasmodium vivax) use a three-band
P. falciparum/Pan test such as the SD Bioline Malaria Ag P.f/Pan 05FK60 (Standard Diagnostics, Kyonggi, Republic of
Korea), hereafter referred to as SD 05FK60, as used by the MSF-Holland clinics in Rakhine state, Myanmar. In spite of
published reports of generally good test performance, medical and paramedical staff on the ground often doubt
the diagnostic accuracy of these RDTs.
Methods: Parallel testing with malaria microscopy and RDT was conducted at two clinics in Rakhine state,
Myanmar, for a period of 14 months as a programmatic response due to doubts and concerns of medical and
paramedical staff into malaria RDTs.
Results: A total of 2,585 blood samples from non-pregnant suspected malaria patients were examined by the SD
05FK60 RDT and microscopy at two clinics in Myanmar from October 2010 to December 2011. The reference
standard microscopy diagnosed 531 P. falciparum and 587 P. vivax or P. malariae mono-infections. The overall
sensitivity for P. falciparum detection by the SD 05FK60 was 90.2% (95% CI: 87.4-92.6) and for P. vivax/P. malariae
79.4% (95% CI: 75.9-82.6). The overall specificity for P. falciparum detection by the SD 05FK60 was 98.5% (95%
CI: 97.7-99.1) and for P. vivax/P. malariae 98.7% (95% CI: 97.9-99.2). The sensitivity for P. falciparum was >91% for
parasitaemia levels of >100-1,000 parasites/μl and increased for P. vivax/P. malariae with the parasitaemia level but
was overall lower than for P. falciparum 25/408 and 13/420 cases, respectively, of P. falciparum and non-falciparum
malaria were missed by the RDT.
Conclusion: In field conditions in Myanmar, the SD 05FK60 malaria RDT performed consistent with other reports.
The test detected malaria caused by P. vivax/P. malariae to a lesser extent than P. falciparum infection. Sensitivity
improved with increasing parasitaemia level, however even at higher levels some infections were missed. The SD
05FK60 is adequate for use in settings where high quality microscopy is not available.
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Microscopy is the reference standard for diagnosing mal-
aria but is time consuming and requires considerable
training and experience. It is ill suited as a diagnostic tool
in settings where the case load is high and resources lim-
ited [1,2]. Lateral-flow immunoassays (LFIs), often called
rapid diagnostic tests (RDTs), are an attractive alternative
as they are quick and easy to carry out [1-7]. In practice
however, malaria is often diagnosed solely on the basis of
clinical symptoms, without using either method; this re-
sults in over-treatment of malaria and the risk of missing
true underlying pathologies. To improve the accuracy of
malaria diagnosis and avoid unnecessary treatment, the
World Health Organization (WHO) recommends para-
sitological confirmation of malaria whenever possible, by
RDT or by microscopy [1,8-11].
Among the newer generation of malaria RDTs are
three-band tests that detect both the Plasmodium falcip-
arum-specific antigen histidine-rich protein 2 (HRP2)
and the pan-Plasmodium-specific lactate dehydrogenase
(pLDH), expressed in the four most common malaria
parasite species [P. falciparum, Plasmodium ovale, Plas-
modium malariae and Plasmodium vivax [6,12-16].
In 2009, Médecins Sans Frontières (MSF) introduced
routine use of HRP2/pan-pLDH RDTs into its pro-
grammes at sites where both P. falciparum and non-
falciparum malaria are present (i e, Southeast Asia, the
Americas and the Ethiopian highlands). In Myanmar,
which has an enormous malaria burden, accounting for
7% of all malaria cases in Southeast Asia and India [7],
P. vivax is second only to P. falciparum as the cause of
malaria, so the test chosen was the SD Bioline 05F
K60 Malaria Ag P.f/Pan (Standard Diagnostics, Kyonggi,
Republic of Korea), hereafter referred to as SD 05FK60.
The choice was made for the SD 05FK60 because it was
one of the best performing assays in the WHO/TDR (Spe-
cial Programme for Research and Training in Tropical
Diseases)/FIND (Foundation for Innovative New Diagnos-
tics)/CDC (Centers for Disease Control) evaluation in
Round 1 and because continuous supply and importation
to Myanmar could be guaranteed. However, since 2007,
evaluations of the SD 05FK60 were conducted in returned
travellers or as mentioned before by the WHO/TDR/
FIND/CDC programme but not on a field site. In these
evaluations, the SD 05FK60 showed good performance for
detection of malaria caused by P. falciparum, with varying
results for P. vivax detection [17-22].
However, in spite of the generally good performance of
malaria RDTs, their use on the ground can be problem-
atic: medical staff frequently mistrust the results and prob-
lems with the products (e g, poor migration of blood and
buffer, faint lines, incorrect placement of the lateral-flow
strip in the cassette) are encountered regularly [23-25].
This often results in low coverage of RDT implementationand poor adherence to RDT results (as the basis for treat-
ment decisions) in clinical practice [26]. In order to moni-
tor the performance of this newly introduced RDT in
MSF’s programmes in Myanmar and to respond to clini-
cians’ concerns of poor RDT performance, it was decided
to test patients in parallel with microscopy and RDT until
the end of 2011 in our programmes in Rakhine State. In
Myanmar, approximately 68% of the population of over 60
million total, is thought to be at risk for malaria with the
high risk areas concentrated near international borders,
including Rakhine state. The yearly burden in the entire
country is to be over two million cases [16].Methods
Investigation sites and procedures
MSF has been working in Myanmar’s Rakhine State since
1993. Primary health care (PHC), including the diagnosis
and treatment of malaria, is provided free of charge at two
clinics, in Sittwe and Thetkalpyin, located in the eastern
region of Rakhine. All patients presenting at the Sittwe
and Thetkalpyin clinics with fever or a history of fever in
the prior 24 hours were immediately tested for malaria on
capillary blood with the SD 05FK60 RDT. In addition, a
slide was prepared from the same capillary sample and ex-
amined separately in the laboratory regardless of the SD
05FK60 result. The laboratory technician was not aware of
the SD 05FK60 result when examining the smear. Preg-
nant women screened for malaria as part of antenatal care
received the same procedure but were not included in this
analysis.
This routine parallel testing of the described population
was carried out from 25 October, 2010 until 23 December,
2011 with one month of data lost (23 February to 28
March 2011) as a result of security incidents in eastern
Rakhine State.Microscopy
Thick and thin blood films were prepared and stained
with 10% Giemsa solution (pH 7.2) for 10 min and exam-
ined by light microscopy using x1,000 magnification. At
least 200 fields had to be examined before designating a
sample ‘negative’, or more accurately, ‘no malaria para-
sites seen’. Positive findings were graded on the thick
smear using the ‘plus’ system scale: + (1 to 9 trophozoites
in 100 fields); ++ (1 to 10 trophozoites in 10 fields); +++
(1 to 10 trophozoites per field); ++++ (>10 trophozoites
per field). These scores were used to estimate parasite
densities: + = 10 to 90 parasites/μl; ++ = 100 to 1,000 par-
asites/μl, +++ = 1,000 to 10,000 parasites/μl; ++++ = >
10,000 parasites/μl, assuming a white blood cell count of
8,000/μl. The species was identified using the thin
smear.
Table 2 Performance of SD Bioline Malaria Ag P.f/Pan









Sensitivity (95% CI) 90.2 (87.4-92.6) 79.4 (75.9-82.6)
Specificity (95% CI) 98.5 (97.7-99.1) 98.7 (97.9-99.2)
PPV (95% CI) 96.0 (93.9-97.5) 96.3 (94.2-97.8)
NPV (95% CI) 96.2 (95.0-97.2) 91.6 (90.0-93.0)
LR + (95% CI) 60.3 (39–93.2) 59.0 (37.2-93.5)
LR- (95% CI) 0.10 (0.08-0.13) 0.21 (0.18-0.25)
A total of 2,585 blood samples was examined at the Sittwe and Thetkalpyin
clinics, Rakhine State, Myanmar.
PPV: positive predicted value; NPV: negative predictive value; LR: likelihood
ratio; LR+: sensitivity/(1–specificity); LR–: (1–specificity)/sensitivity.
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The SD 05FK60 RDT is a three-band lateral-flow
immunochromatographic antigen detection test in a cas-
sette format and testing was carried out according to the
manufacturer’s instructions. Readings were taken in day-
light, assisted by standard electric lighting. A negative re-
sult is indicated by the presence of a single line, the ‘C’
control line, in the result window. A P. falciparum-posi-
tive result was indicated by presence of two colour bands,
the P. falciparum test line and the ‘C’ control line. The
presence of the ‘Pan’ test line and the ‘C’ control line
(again, two colour bands) indicated a P. vivax, P. ovale. or
P. malariae-positive result or a mixed non-falciparum in-
fection. The presence of three colour bands, the ‘P. falcip-
arum’ and ‘Pan’ test lines and the ‘C’ control line indicates
a P. falciparum-positive result or a mixed infection. In
cases where the control line did not appear, the results
were interpreted as invalid and the test repeated with a
new device.
Statistical analysis
Data were entered in an Excel file and analysed using Stata
11.0 statistical software (Stata Corporation, College Sta-
tion, Texas, USA). Samples with pure gametocytaemia
were considered negative. Microscopically identified mixed
infections were considered separately (Table 1) and not in-
cluded in the calculations of test accuracy (Table 2). Sensi-
tivity, specificity and predictive values were calculated with
95% confidence intervals (CI) for the detection of P. falcip-
arum and non-falciparum species separately. When calcu-
lating the performance parameters for P. falciparum all
negative samples plus all P. falciparum positive samples by
microscopy contributed to the analysis. Similarly for the
non-falciparum analysis all negative samples and all non-
falciparum positive samples by microscopy contributed to
the analysis. Likelihood ratios were calculated using the
following formulae: LR + = sensitivity/(1–specificity) and
LR– = (1–specificity)/sensitivity (Table 2).
Quality control
All malaria RDTs purchased by MSF must pass the WHO
lot-testing programme before being shipped to field sitesTable 1 Malaria diagnosis: microscopy compared with rapid d
SD Bioline Malaria Ag P.f/Pan
Microscopy result No. of
samples
Negative (%) P. fa
(control band only) (P. fa
No parasites seen 1,337 1,306 (97.7) 13 (1
P. falciparum 531 39 (7.3) 162 (
P. vivax or P. malariae 587 118 (20.1) 3 (0.5
Mixed P.f/pan 130 0 (0.0) 6 (4.6
A total of 2,585 blood samples was examined at the Sittwe and Thetkalpyin clinics,
*SD 05FK60 detects the pan-Plasmodium-specific lactate dehydrogenase (pLDH) exp[27]. In addition, the programme follows the WHO Mal-
aria Microscopy Quality Assurance recommendation [28].
In accordance with this protocol, slides were sent to the
Shoklo Malaria Research Unit (SMRU) in Mae Sot,
Thailand, for external quality control.
Ethical statement
This manuscript reports a descriptive retrospective ana-
lysis of routinely collected data, and therefore no protocol




Between 25 October, 2010 and 23 December, 2011, a
blood sample was obtained from each of 2,585 non-
pregnant individuals attending the Sittwe and Thetkalpyin
clinics in Rakhine State and suspected to have malaria in-
fection. Baseline characteristics of the included population
are shown in Table 3.
Microscopy and RDT results are shown in Table 1: 531/
2,585 (20.5%) patients were infected with P. falciparum,
587/2,585 (22.7%) with P. vivax or P. malariae. and 1,337/
2,585 (51.7%) tested negative; 130 (5.0%) mixed infections
(i.e., six from Sittwe, 124 from Thetkalpyin) were foundiagnostic test SD Bioline Malaria Ag P.f/Pan 05FK60
(05FK60)
lciparum (%) Pan* (%) P.f/Pan (%)
lciparum band only) (Pan band only) (P.f and pan band)
.0) 11 (0.8) 7 (0.5)
30.5) 13 (2.5) 317 (59.7)
) 454 (77.3) 12 (2.0)
) 2 (1.5) 122 (93.9)
Rakhine State, Myanmar.
ressed in P. falciparum, P. vivax, P. ovale and P. malariae).
Table 3 Baseline characteristics of the study population
Male 1,327 (51.3)
Mean age in years (range) 10.9 (0.1-94)
Mean temperature in °C (range) 39.2 (35.0-42.0)
Temperature ≥37.5°C 2,162 (85.0)
Parasitaemia level - 1,337 (51.7)
Parasitaemia level + 161 (6.2)
Parasitaemia level ++ 132 (5.1)
Parasitaemia level +++ 340 (13.2)
Parasitaemia level ++++ 615 (23.8)
The included population for the study was all non-pregnant patients
presenting at the Sittwe and Thetkalpyin clinics, Rakhine State, Myanmar with
fever or a history of fever prior 24 hours.
Data are presented as numbers (%) unless otherwise indicated.
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tion was assessedTest performance
Sensitivity, specificity and predictive values of the SD
05FK60 for detection of malaria are shown in Table 2. The
overall sensitivity for P. falciparum detection by the SD
05FK60 was 90.2% (95% CI: 87.4-92.6) and for P. vivax/
P. malariae 79.4% (95% CI: 75.9-82.6). The overall specifi-
city for P. falciparum detection by the SD 05FK60 at both
clinics was 98.5% (95% CI: 97.7-99.1) and for P. vivax/
P. malariae 98.7% (95% CI: 97.9-99.2).
The positive predictive value (PPV) for P. falciparum
detection by the SD 05FK60 in both projects was 96.0%
(95% CI: 93.9-97.5%) and for P. vivax 96.3% (95% CI: 94.2-
97.8%) at prevalence levels of 28% and 31%, respectively.
The negative predictive value (NPV) for P. falciparum de-
tection by the SD 05FK60 in both projects was 96.3%
(95% CI: 94.9-97.5%) and for P. vivax 92.5% (95% CI: 90.7-
94.2%). Test accuracy indices were calculated separately
for the two clinics but no significant difference in per-
formance was observed.Table 4 Sensitivity by parasitaemia level of the SD 05FK60 ra
Parasite density P. falciparum
Number of RDT positives/







Chi-square test for trend p <0.05
A total of 2,585 blood samples was examined at the Sittwe and Thetkalpyin clinics,
Estimated parasite densities: + = 10–90 p/μl, ++ = 100–1,000 p/μl, +++ = 1,000-10,00
detected by SD Bioline Malaria Ag P.f/Pan (05FK60).2.5% (13/531) of the P. falciparum infections were
wrongly identified by the SD 05FK60 as non-falciparum
infections (Table 1). Of those misclassified two samples
had a +, one sample a ++, four samples a +++ and six
samples a ++++ parasitaemia level.
Of the non-falciparum infections 2.5% (15/587) were
misclassified as P. falciparum or mixed infection (Table 1):
0.5% (3/587) were positive on the P. falciparum band of
which one samples had a ++ and one sample ++++ para-
sitaemia level. 2.0% (12/587) of the non-falciparum sam-
ples were positive on the P. falciparum and pan-band of
which seven had a +++ and five ++++ parasitaemia level.
Of the 130 mixed infections 122 were correctly identified
by the SD 05FK60 with a positive P. falciparum and pan-
band. Two samples only had a positive pan-band and six
samples were only positive on the P. falciparum band.
Table 4 shows the malaria detection rate with SD
05FK60 at different levels of parasitaemia. The sensitivity
varied between 90.5% and 95.8% for P. falciparum speci-
mens and between 69.8% and 97.7% with a ++ to ++++
parasitaemia level. The sensitivity increased consistently
with increasing parasitaemia for P. vivax/P. malariae
(p < 0.005). 25/408 and 13/420 cases with +++ and ++++
parasitaemia levels, respectively, of P. falciparum and
non-falciparum malaria were missed by the RDT.Quality control
The quality control team at the Shoklo Malaria Research
Unit (SMRU) in Mae Sot, Thailand, cross-checked 450
slides (225 negative and 225 positive) from MSF’s projects
in Myanmar from the year 2010, and 250 slides (125 posi-
tives and 125 negatives) from MSF’s projects in Eastern
Rakhine State in Myanmar from the year 2011.
The overall agreement between the positive results
had a kappa value of 0.96 (95% CI: 0.93; 0.99) for 2010
and 0.91 (95% CI: 0.85, 0.98) for 2011, indicating very
good agreement. The overall sensitivity was 98.3% (225/
229) in 2010 and 98.4% (123/125) in 2011; overallpid diagnostic test
P. vivax/P. malariae
sitivity % Number of RDT positives/









0 p/μl, ++++ = >10,000 p/μl. N: total number of blood samples; n: total
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111) in 2011.Discussion
Commercially available HRP-2/pLDH tests have been
evaluated previously in Myanmar [29,30] but evaluations
of the SD 05FK60 are available only from other areas and
were conducted before 2007 [17-22]. The study showed
overall good performance for the SD 05FK60 RDT in the
identification of malaria infections caused by P. falcip-
arum and satisfactory results for non-falciparum infec-
tions. The poorer detection and identification of P. vivax/
P. malariae than that of P. falciparum is consistent with
other evaluations of the SD 05FK60 and pan-pLDH tests
in general [17-22].
However, it should be pointed out that in Round 1 of
the WHO/TDR/FIND/CDC evaluation, the panel detec-
tion score (PDS) of the SD 05FK60 reported at pa-
rasitaemia levels of 200 parasites/μl was 96.2% for
P. falciparum and 35.0% for P. vivax [18]. The same prod-
uct was retested in Round 3 of this evaluation and showed
a slightly decreased PDS of 92.9% for P. falciparum along
with an improved detection score of 97.1% for P. vivax
[19]. It is unclear which version of the product was re-
ceived in the programme - the catalogue number always
remained the same – and this inconsistency is a com-
monly encountered problem by MSF when an in vitro
diagnostic product is changed.
The sensitivity of the SD 05FK60 improves with in-
creasing parasitaemia. This is a well-known limitation of
RDTs. Less expected were the findings that 25 P. falcip-
arum infections and 12 P. vivax/P. malariae infections
with +++ or ++++ parasitaemia were undetected by the
SD 05FK60. The non-detection of P. falciparum infec-
tions at high parasitaemia levels could be explained by
the prozone effect [31-33] or by deletion of the histidine-
rich repeat region in the HRP-2 gene [34]. It was not
possible to conduct further molecular analysis of the
Plasmodium cohort in the area to undermine this argu-
ment. However, this does not explain the false negative
pan-pLDH band.
Translating these results into the impact on patients, 52
(10.2%) of a total 531 P. falciparum mono-infections
would have been missed by using the RDT without mi-
croscopy. Although the specificity has been high for both
P. falciparum and non-falciparum infections: 98.5% and
98.7% respectively, thirteen infections were misidentified
as P. vivax/P. malariae malaria and as a result would have
been treated with chloroquine, a drug to which P. falcip-
arum is unlikely to be susceptible [35]. Considering the
P. vivax/P. malariae cases, 121 out of 587 (20.6%) individ-
uals would have not received any malaria treatment des-
pite being infected. Only 31 individuals out of a total of1,337 (2.3%) would have been unnecessarily treated with
anti-malarials on the basis of RDT.
Although the results of the performance of the SD
05FK60 are satisfactory, MSF decided to opt for micros-
copy as the first choice for malaria diagnosis in its
programmes in Rakhine State, Myanmar. This was a
pragmatic decision based on the clinicians’ greater trust
in microscopy, particularly in light of the cases with high
parasitaemia that would have been missed if microscopy
had not been used in addition to the RDT. MSF reserves
RDTs for use in decentralized settings and where a high
number of patients precludes microscopy. Therefore
MSF decided to continue using microscopy in the two
clinics in Rakhine State, Myanmar for the routine diag-
nosis of malaria, although RDTs have been found to be
more cost-effective and more feasible in other settings
[36-38].
This study has several limitations. The data were col-
lected as part of routine programmatic activities and were
unlinked to patient records. Thus, it was impossible to
collect clinical information, such as recent intake of anti-
malarials or the presence of other factors, which may have
influenced the results. Another limitations is that the +
system has been used to grade parasitaemia instead of a
parasite count. This less accurate estimation may have
influenced the results on sensitivity especially in the strati-
fied analysis of parasitaemia levels.
It is important to note that the described data were
obtained in true field conditions, i e, conditions that were
suboptimal in terms of RDT storage and handling and
staff expertise, and non-standardized specimens may have
been present. It is known that such factors influence RDT
performance [39,40], but it is difficult to optimize all these
variables under difficult real-life conditions. However, this
is also a strength of the study, as it represents test per-
formance under field conditions.
MSF is able to train and maintain good malaria micros-
copy in its field settings. However, this may not be possi-
ble in a wider public health arena. In 2006 the WHO
estimated that, if the recommendation to obtain parasito-
logical confirmation of malaria before prescribing treat-
ment were to be followed, screening would need to be
scaled up from 122 million to 780 million tests each year
in Southeast Asia alone, a 600% increase. Such scaling up
would undoubtedly be difficult to achieve without the use
of simple, reliable RDTs [7].Competing interests
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